Evidence map›Paper›PMID 34475958›Full record

ArticleStem cells international2021

miR-370-3p as a Novel Biomarker Promotes Breast Cancer Progression by Targeting FBLN5.

Jiahui Mao, Lingxia Wang, Junying Wu, Yichun Wang, Huiyan Wen, Xueming Zhu, Bo Wang, Huan Yang

Abstract read
In one paragraph

Article in Stem cells international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiahui MaoDepartment of Central Laboratory, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212013 Jiangsu, China.
Lingxia WangDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.
Junying WuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.
Yichun WangDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.
Huiyan WenDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.
Xueming ZhuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.
Bo WangDepartment of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.ORCID https://orcid.org/0000-0001-5654-6617
Huan YangDepartment of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, 215004 Jiangsu, China.ORCID https://orcid.org/0000-0002-3106-490X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

miRNAs play a crucial part in multiple biological processes of cell proliferation, migration, apoptosis, and chemoresistance. In cancer, miRNAs can be divided into oncogenes or tumor suppressors on the basis of their functions in the carcinogenic process. The purpose of this study was to explore the roles and clinical diagnostic value of miR-370-3p in breast cancer. Our results demonstrated that miR-370-3p significantly promoted proliferation, metastasis, and stemness of breast cancer

Identifiers

PMID34475958
PMCPMC8407987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.